Additional file 1 of Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

MLA

Mercieca-Bebber, R., et al. Additional File 1 of Patient-Reported Outcome (PRO) Results from the AGITG DOCTOR Trial: A Randomised Phase 2 Trial of Tailored Neoadjuvant Therapy for Resectable Oesophageal Adenocarcinoma. Jan. 2022. EBSCOhost, https://doi.org/10.6084/m9.figshare.19366069.v1.

APA

Mercieca-Bebber, R., Barnes, E. H., Wilson, K., Samoon, Z., Walpole, E., Mai, T., Ackland, S., Burge, M., Dickie, G., Watson, D., Leung, J., Wang, T., Bohmer, R., Cameron, D., Simes, J., Gebski, V., Smithers, M., Thomas, J., Zalcberg, J., & Barbour, A. P. (2022). Additional file 1 of Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma. https://doi.org/10.6084/m9.figshare.19366069.v1

Chicago

Mercieca-Bebber, R., E. H. Barnes, K. Wilson, Z. Samoon, E. Walpole, T. Mai, S. Ackland, et al. 2022. “Additional File 1 of Patient-Reported Outcome (PRO) Results from the AGITG DOCTOR Trial: A Randomised Phase 2 Trial of Tailored Neoadjuvant Therapy for Resectable Oesophageal Adenocarcinoma,” January. doi:10.6084/m9.figshare.19366069.v1.